JoaquinaCelebreBarandaMDFACP

Oncology • Westwood, KS

Gastrointestinal Cancer

George and Floriene Lieberman Endowed Professor Medical Director, Early Phase Program, Clinical Research Center University of Kansas Cancer Center

Join to view full profile

Dr. Baranda is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Baranda's full profile

Already have an account?

Office
2650 Shawnee Mission Pkwy
Westwood, KS 66205
Phone+1 913-588-1227

Fax+1 913-588-4085

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 1991 - 1994
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1988 - 1991
University of Santo TomasClass of 1985

Certifications & Licensure

KS State Medical License 2003 - 2025
MO State Medical License 2021 - 2025
CA State Medical License 1991 - 2020
IL State Medical License 1990 - 1993
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Erlotinib in Treating Patients With Barrett Esophagus Start of enrollment: 2007 Jul 01
Unknown status
Phase 1
A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer Start of enrollment: 2011 Feb 01
Completed
Phase 1
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Start of enrollment: 2013 May 01
Terminated
Phase 3
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer Start of enrollment: 2015 Oct 12
Completed
Phase 2
A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies Start of enrollment: 2018 Jul 19
Active, not recruiting
Phase 1
A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors Start of enrollment: 2019 Jul 26
Active, not recruiting
Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Start of enrollment: 2020 Oct 27
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

163 citations
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, David Smith, D. Ruether
Journal of Clinical Oncology. 2020-02-07
409 citations
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluor...
Ralf Metzger, Cynthia G. Leichman, Kathleen D. Danenberg, Peter V. Danenberg, Heinz-Josef Lenz
Journal of Clinical Oncology. 1998-01-01
299 citations
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
Heinz-Josef Lenz, Cynthia G. Leichman, Kathleen D. Danenberg, Peter V. Danenberg, Susan Groshen
Journal of Clinical Oncology. 1996-01-01

Authored Content

Expanding access to early phase trials: the CATCH-UP.2020 experienceDecember 2022

Press Mentions

Increasing Diversity in Clinical TrialsOctober 22nd, 2023

Professional Memberships

American Society of Clinical Oncology - ASCO
Member